Biotin
- Generic Name
- Biotin
- Brand Names
- Concept Ob, Infuvite, Infuvite Pediatric, Irospan 24/6 Kit, Mvi Pediatric
- Drug Type
- Small Molecule
- Chemical Formula
- C10H16N2O3S
- CAS Number
- 58-85-5
- Unique Ingredient Identifier
- 6SO6U10H04
- Background
A water-soluble, enzyme co-factor present in minute amounts in every living cell. It occurs mainly bound to proteins or polypeptides and is abundant in liver, kidney, pancreas, yeast, and milk.
- Indication
For nutritional supplementation, also for treating dietary shortage or imbalance.
- Associated Conditions
- Vitamin Deficiency
- Associated Therapies
- Nutritional supplementation
The Possible Efficacy and Safety of L-carnitine and Biotin as Adjunctive Therapies in Children With Moderate Persistent Asthma
- Conditions
- Moderate Persistent Asthma
- Interventions
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 66
- Registration Number
- NCT05632549
- Locations
- ๐ช๐ฌ
Tanta University Hospital, Tanta, Gharbia, Egypt
Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease
- Conditions
- Sickle Cell DiseaseSickle Cell Anemia
- Interventions
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2024-02-13
- Target Recruit Count
- 22
- Registration Number
- NCT04476277
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Red Blood Cell Survival in Sickle Cell Disease
- Conditions
- Sickle Cell Disease
- Interventions
- Device: INTERCEPT Blood System
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Marianne Yee
- Target Recruit Count
- 40
- Registration Number
- NCT04426591
- Locations
- ๐บ๐ธ
Hughes Spalding Children's Hospital, Atlanta, Georgia, United States
๐บ๐ธChildrens Healthcare of Atlanta, Atlanta, Georgia, United States
๐บ๐ธGrady Health System, Atlanta, Georgia, United States
Evaluation of the Incidence of Relapses in Patients With Biotin-treated Progressive Multiple Sclerosis
- Conditions
- Progressive Multiple Sclerosis
- Interventions
- Other: propensity score
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2018-06-11
- Lead Sponsor
- University Hospital, Clermont-Ferrand
- Target Recruit Count
- 3000
- Registration Number
- NCT03552211
- Locations
- ๐ซ๐ท
CHU Clermont-FERRAND, Clermont-Ferrand, France
Safety and Tolerability of High Dose Biotin in Patients With Amyotrophic Lateral Sclerosis
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- American University of Beirut Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT03427086
- Locations
- ๐ฑ๐ง
American univeristy of Beirut medical center, Beirut, Lebanon
RBC Lifespan Measurement in Diabetic Children
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Guohua An
- Target Recruit Count
- 6
- Registration Number
- NCT03073070
- Locations
- ๐บ๐ธ
University of Iowa, Iowa City, Iowa, United States
BioRBC Survival in Adults With Prior Antibody Response to BioRBCs
- First Posted Date
- 2014-03-04
- Last Posted Date
- 2021-04-29
- Lead Sponsor
- John A Widness
- Target Recruit Count
- 3
- Registration Number
- NCT02077751
- Locations
- ๐บ๐ธ
University of Iowa, Iowa City, Iowa, United States
Mechanisms Accounting for Unexplained Anemia in the Elderly
- First Posted Date
- 2012-04-06
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- National Institute on Aging (NIA)
- Target Recruit Count
- 58
- Registration Number
- NCT01572506
- Locations
- ๐บ๐ธ
National Institute of Aging, Clinical Research Unit, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.